

Supplemental Table I. Diagnosis, procedure, and medication codes used to define the study population

| Category | Type of code | Code |
|----------------------------------|---------------------------|--|
| <i>Inclusion criteria</i> | | |
| | | <ul style="list-style-type: none">• Apixaban: 617001ATB, 617002ATB• Dabigatran: 613701ACH, 613702ACH, 613703ACH• Edoxaban: 643601ATB, 643602ATB, 643603ATB• Rivaroxaban: 511401ATB, 511402ATB, 511403ATB, 511404ATB• Warfarin: 249101ATB, 249102ATB, 249103ATB, 249104ATB, 249105ATB, 249106ATB, 249107ATB, 249108ATB, 249109ATB |
| Antithrombotics | Medication code | <ul style="list-style-type: none">• Aspirin: 110701ATE, 110705ACE, 111001ACE, 111001ATB, 111001ATE, 111002ATE, 111003ACE, 111003ATE• Clopidogrel: 136901ATB, 492501ATB, 495201ATB, 498801ATB, 501501ATB• Aspirin/clopidogrel: 517900ACE, 517900ACH, 517900ATE• Prasugrel: 597301ATB, 597302ATB• Ticagrelor: 615901ATB, 615902ATB• Ticlopidine: 239201ATB, 239202ATB |
| AF | ICD-10 code ¹⁾ | I48 |

| | | |
|---|---------------------------|---|
| | | <ul style="list-style-type: none"> • Congestive heart failure: I50 • Hypertension: I10-I15 • Diabetes mellitus: E10-E14 • Stroke: I63, I693, G459 • Vascular disease: I21, I252, I70-I73 |
| CHA ₂ DS ₂ -VASc score | ICD-10 code ¹⁾ | |
| <i>Exclusion criteria</i> | | |
| | ICD-10 code ¹⁾ | I05, I08, I09, I34, Q23, T820, T826, Z952, Z953, Z954 |
| Valvular AF/ prosthetic heart valves | Procedure code | M6580, M6581, M6582, O1791, O1792, O1793, O1794, O1795, O1796, O1797, O1798, O1799, M6531, M6532, M6533, O1690, O1730, 1740, O1750, O1760, O1770, O1781, O1782, O1783, O1810, O1826 |
| Venous thromboembolism | ICD-10 code ¹⁾ | I636, I676, I801, I802, I803, I808, I809, I81, I822, I823, I829, I26 |
| Hip or knee replacement | Procedure code | N0711, N0715, N1711, N1715, N1721, N1725, N2070, N2072, N2077, N2710, N2712, N2717, N3710, N3712, N3717, N3720, N3722, N3727, N4710, N4712, N4717, N4720, N4722, N4727 |
| End-stage of chronic kidney disease/ dialysis/ kidney transplant / pericarditis | ICD-10 code ¹⁾ | N185, T824, Y602, Y612, Y622, Y841, Z49, Z992, E1022, E1122, E1222, E1322, E1422, Z940, I30, I31, I32 |
| Transient AF or cardiac surgery | ICD-10 code ¹⁾ | E05, I422 |

| | |
|----------------|--|
| Procedure code | M5880, M6540, M6542, M6545, M6547, M6511 |
|----------------|--|

Abbreviations: AF, atrial fibrillation; ICD-10, International Classification of Diseases, Tenth Revision.

¹⁾ Main and all subdiagnosis codes were used.

Supplemental Table II. HAS-BLED score

| Category | ICD-10 code ¹⁾ | Point |
|-------------------------|--|-------|
| Hypertension | I10-I15 | 1 |
| Abnormal renal function | N183, N184 | 1 |
| Abnormal liver function | B15, B16, B17, B18, B19, C22, K70, K71, K72, K73, K74, K75, K76, K77, D684, I982, I983, Z944 | 1 |
| Stroke | I63, I693, G459 | 1 |
| | <ul style="list-style-type: none">• Intracranial hemorrhage: I60, I61, I62, I690, I691, I692, S064, S065, S066, S068 <u>AND</u> procedure code for brain CT/MRI (HA441, HA451, HA461, HA471, HA851, HE101, HE102, HE135, HE201, HE202, HE235, HE301, HE302, HE401, HE402, HE501, HE502, HE535) <u>AND</u> hospitalization• Gastrointestinal bleeding: I850, I983, K2211, K226, K228, K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K290, K3181, K5521, K625, K920, K921, K922• Other bleeding: D62, H448, H3572, H356, H313, H210, H113, H052, H470, H431, I312, N020-N029, N421, N831, N857, N920, N923, N930, N938, N939, M250, R233, R040, R041, R042, R048, R049, T792, T810, N950, R310, R311, R318, R58, T455, Y442, D683• Transfusion (procedure code): X1001, X1002, X2011, X2012, X2021, X2022, X2031, X2032, X2041, | |

| | | |
|---------------------------|--|---|
| | X2042, X2051, X2052, X2061, X2062, X2071, X2072, X2081, X2082, X2091, X2092, X2101, X2102, X2111, X2112, X2121, X2122, X2131, X2132, X2141, X2142, X3010 | |
| Age > 65 | - | 1 |
| Antiplatelet or NSAID use | <ul style="list-style-type: none"> • Antiplatelets: 110701ATE, 110705ACE, 111001ACE, 111001ATB, 111001ATE, 111002ATE, 111003ACE, 111003ATE, 110706ATB, 110702ATB, 110902BIJ, 110802ATB, 110701ATB, 254300ACH, 394401ATB, 110704ATB, 110801ATB, 136901ATB, 492501ATB, 495201ATB, 498801ATB, 501501ATB, 517900ACE, 517900ACH, 517900ATE, 100431BIJ, 100430BIJ, 133201ACR, 133201ATB, 133201ATD, 133202APD, 133202ATB, 133202ATD, 133203ACR, 133203ATR, 147201ATB, 147202BIJ, 147203ATB, 597301ATB, 597302ATB, 615901ATB, 615902ATB, 239201ATB, 239202ATB, 240230BIJ | 1 |
| Alcoholism | F10, K70, X45, X65, Y15, Y90, Y91, E244, G312, G621, G721, I426, K292, K860, O354, P043, Q860, T510, Z502, Z714, Z721 | 1 |

Abbreviations: ICD-10, International Classification of Diseases, Tenth Revision; NSAID, nonsteroidal anti-inflammatory drugs.

¹⁾ Main and all subdiagnosis codes were used.

Supplemental Table III. Charlson Comorbidity Index


| Category | ICD-10 code ¹⁾ | Point |
|---------------------------------------|--|-------|
| Cerebrovascular disease | G45, G46, H340, I60-I69 | 1 |
| Congestive heart failure | I099, I110, I130, I132, I255, I420, I425-I429, I43, I50, P290 | 1 |
| Chronic pulmonary disease | I278, I279, J40–J47, J60–J67, J684, J701, J703 | 1 |
| Dementia | F00–F03, F051, G30, G311 | 1 |
| Diabetes without chronic complication | E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121, E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149 | 1 |
| Mild liver disease | B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762-K764, K768, K769, Z944 | 1 |
| Myocardial infarction | I21, I22, I252 | 1 |
| Peripheral vascular disease | I70, I71, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z959 | 1 |
| Peptic ulcer disease | K25–K28 | 1 |
| Rheumatologic disease | M05, M06, M32–M34 M315M351, M353, M360 | 1 |
| Diabetes with chronic complication | E102–E105, E107, E112–E115, E117, E122-E125, E127, E132–E135, E137, E142–E145, E147 | 2 |

| | | |
|---|--|---|
| Hemiplegia or paraplegia | G041, G114, G801, G802, G81, G82, G830-G834, G839 | 2 |
| Any malignancy, including leukemia and lymphoma | C00–C26, C30–C34, C37–C41, C43, C45–C58, C60–C76, C81–C85, C88, C90–C97, | 2 |
| Renal disease | I120, I131, N032-N037, N052-N057, N18, N19, N250, Z490-Z492, Z940, Z992 | 2 |
| Moderate or severe liver disease | I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767 | 3 |
| AIDS/HIV | B20–B22, B24 | 6 |
| Metastatic solid tumor | C77–C80 | 6 |

Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; ICD-10, International Classification of Diseases, Tenth Revision.

¹⁾ Main and all subdiagnosis codes were used.


Supplemental Figure I. Treatment patterns of antithrombotics before and after the introduction of NOACs without duplicate patients who were included in both intake periods



Proportions of patients prescribed each type of antithrombotics before the NOAC introduction (A) according to the HAS-BLED score; (B) according to the CHA₂DS₂-VASc score; (C) according to the comorbidities, and after the NOAC introduction (D) according to the HAS-BLED score; (E) according to the CHA₂DS₂-VASc score; (F) according to the comorbidities.

Abbreviations: MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulants; PAD, peripheral artery disease.

Supplemental Figure II. Clinical factors associated with the choice of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy




Odds ratios for the association of clinical factors with the choice of **(A)** warfarin + antiplatelets versus warfarin before and in the NOAC era; **(B)** NOAC + antiplatelets vs NOAC in the NOAC era.


Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulants; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PAD, peripheral artery disease; PPI, proton pump inhibitor.

Supplemental Figure III. Clinical factors associated with the choice of antithrombotics stratified by gender


(A)




(B)



(C)



(D)



Odds ratios for the association of clinical factors with the choice of (A) antiplatelets versus warfarin before and in the NOAC era among male patients; (B) warfarin/antiplatelets versus NOAC in the NOAC era among male patients; (C) antiplatelets versus warfarin before and in the NOAC era among female patients; (D) warfarin/antiplatelets versus NOAC in the NOAC era among female patients.

Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulants; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PAD, peripheral artery disease; PPI, proton pump inhibitor.